#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Asthma Dermatitis atopic Dementia Alzheimer's type Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Cutaneous T-cell lymphoma recurrent Biotinidase deficiency Vaginal cancer Gastrointestinal stromal tumour Chronic cutaneous lupus erythematosus Splenic marginal zone lymphoma Hairy cell leukaemia recurrent Liposarcoma recurrent Infantile apnoea Neonatal alloimmune thrombocytopenia Neuropathy peripheral Hepatobiliary cancer Glycogen storage disease type II Juvenile chronic myelomonocytic leukaemia Pleomorphic liposarcoma More trials…

    Learn about Rare Diseases

    Pulmonary fibrosis Behcet’s syndrome – Life with Disease Cholangitis sclerosing – Basic Information Hereditary angioedema – Trials in Disease Primary immunodeficiency syndrome – Trials in Disease Waldenstrom’s macroglobulinaemia recurrent – Diagnostics Acquired haemophilia – Trials in Disease Andersen-Tawil syndrome Familial haemophagocytic lymphohistiocytosis – Life with Disease VEXAS syndrome – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    L-Tryptophan Sphingomyelin (Egg) Ampicillin YL201 Sabirnetug Levetiracetam Epinephrine Hydrochloride Incb099280 Atorvastatin Surzebiclimab Atrasentan Hydrochloride Immunostimulants Tenofovir Disoproxil Fumarate Fexofenadine Hydrochloride Festuca Rubra Pollen COLESEVELAM HYDROCHLORIDE Imlifidase Alanyl Glutamine Palonosetron Sodium Valproate More therapies…

    Learn about Your Condition

    Mucopolysaccharidosis I Cardiac arrest Sickle cell disease Pituitary tumour benign Cystic fibrosis Diabetic ketoacidosis Hepatic encephalopathy Erosive oesophagitis Fibrous dysplasia of bone Anxiety disorder Vitamin D deficiency Colorectal cancer metastatic Sarcoma Endometrial cancer metastatic Pterygium More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Evangelismos S.A.

Evangelismos S.A.

Ipsiladou 45-47, Athens, 106 76, Greece

Want to learn more about this study or check if you can participate? Contact us.

  • Study of isatuximab, belumosudil and dexamethasone combination treatment for patients with relapsed or refractory multiple myeloma

    Recruiting

    1 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma refractory
    Investigated Drugs:
    • Belumosudil Mesilate
    • Isatuximab
    • Dexamethasone
    France Germany Greece Italy Norway Portugal

  • Study on the Safety and Effectiveness of GSK4532990 for Adults Aged 18-65 with Alcohol-Related Liver Disease

    Recruiting

    2 1
    Investigated Diseases:
    • Alcoholic liver disease
    Denmark France Germany Greece Italy Poland +2

  • A Phase 3 Study of Efimosfermin Alfa to Assess Safety and Tolerability in Adults with F2‑F3 Stage Metabolic Dysfunction‑Associated Steatohepatitis (MASH)

    Recruiting

    3 1
    Investigated Diseases:
    • Metabolic dysfunction-associated steatohepatitis
    Austria Belgium Bulgaria France Germany Greece +4

  • Safety and Efficacy of Efimosfermin Alfa in Participants with Biopsy‑Confirmed F2‑ or F3‑Stage Metabolic Dysfunction‑Associated Steatohepatitis (MASH)

    Recruiting

    3 1
    Austria Belgium Bulgaria France Germany Greece +4

  • Study on Selatogrel for Preventing Heart Attack in Patients with Recent Heart Attack History

    Recruiting

    3 1
    Investigated Diseases:
    • Acute myocardial infarction
    Investigated Drugs:
    • Selatogrel
    Austria Belgium Bulgaria Croatia Czechia Denmark +17

  • A Phase 3 Study of Once‑Daily Treprostinil Palmitil Inhalation Powder for Adults with Pulmonary Arterial Hypertension

    Not yet recruiting

    3 1
    Investigated Drugs:
    • Treprostinil Palmitil
    Belgium Greece Lithuania Sweden

  • Efficacy and Safety of Once‑Daily Oral ASC30 in Adults with Obesity or Overweight: A Phase III Randomized Placebo‑Controlled Trial

    Not yet recruiting

    3 1
    Czechia Germany Greece

  • A Phase III Study of ASC30 Sodium for Weight Loss in Adults with Obesity or Overweight and Type 2 Diabetes

    Not yet recruiting

    3 1
    Investigated Diseases:
    • Diabetes mellitus
    • Obesity
    • Overweight
    Czechia Germany Greece Poland

  • Study of zenagamtide versus insulin glargine in adults with type 2 diabetes and high cardiovascular risk uncontrolled on oral medications

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Type 2 diabetes mellitus
    Investigated Drugs:
    • Insulin Glargine
    Bulgaria Czechia Germany Greece Italy Poland +1

  • Ramantamig (JNJ-79635322) with drug combination versus standard therapy in newly diagnosed multiple myeloma patients not eligible for stem cell transplant

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • IGG1 TRISPECIFIC MONOCLONAL ANTIBODY AGAINST T-CELL RECEPTOR CD3, B-CELL MATURATION ANTIGEN AND G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D
    • Bortezomib
    • Daratumumab
    Czechia France Germany Greece Italy The Netherlands +3
Previous Page
1 … 4 5 6 7 8 … 14
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!